The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, shares the preliminary results of a Phase I study (NCT03269136) of elranatamab (PF-3135), a bispecific monoclonal antibody, in relapsed/refractory (R/R) multiple myeloma. Elranatamab is targeted to BCMA, an antigen that is highly expressed on the surface of myeloma cells. It additionally targets T-cell expressed-CD3 and, through this, can exert T-cell cytotoxic activity against myeloma cells. The study trialed subcutaneous (SC) administration of the drug, given its potential to reduce the maximum concentration and associated cytokine release syndrome (CRS) occurrence. The dose-escalation stage proved elranatamab to be safe, with manageable adverse events and no dose-limiting toxicities. The overall response rate was significantly higher in patients receiving the highest two dose levels, compared to that of all four doses combined. The effect of SC dosing on the maximum concentration allowed the use of higher doses than IV, without increasing CRS severity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting: GenMab, Amgen, Boehringer Ingelheim, Janssen, Bristol-Myers Squibb
Research funding: Genentech, Pfizer, Janssen, Bristol-Myers Squibb
Patent: Serametrix
